Full Library
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
Resource type
Journal Article
Authors/contributors
- Chavaz, Lara (Author)
- Royston, Léna (Author)
- Masouridi-Levrat, Stavroula (Author)
- Mamez, Anne-Claire (Author)
- Giannotti, Federica (Author)
- Morin, Sarah (Author)
- Van Delden, Christian (Author)
- Chalandon, Yves (Author)
- Neofytos, Dionysios (Author)
Title
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
Abstract
In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.
Publication
Open Forum Infectious Diseases
Date
2023-04-01
Volume
10
Issue
4
Pages
ofad169
Journal Abbr
Open Forum Infectious Diseases
Accessed
5/6/23, 7:06 AM
ISSN
2328-8957
Library Catalog
Silverchair
Citation
Chavaz, L., Royston, L., Masouridi-Levrat, S., Mamez, A.-C., Giannotti, F., Morin, S., Van Delden, C., Chalandon, Y., & Neofytos, D. (2023). CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 10(4), ofad169. https://doi.org/10.1093/ofid/ofad169
ORGANISMS
HEME-ONC AND CELLULAR THERAPIES
Link to this record